OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC
ASCO 2020 Lung Cancer Highlights - Journal of Oncology Navigation & Survivorship
Comparisons between the CheckMate 227 trial and simulation, overall... | Download Scientific Diagram
Immunotherapy in mNSCLC - ASCO 2021: Key NSCLC Studies - Lung Cancer - 2021 ASCO Virtual Annual Meeting - Health Disparities - Clinical Care Options
Update Confirms 5-Year Survival Benefit With Dual Immune Checkpoint Blockade in NSCLC
ASCO 2022: Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): Results from CheckMate 227.
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis - The Lancet Oncology
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC - ILCN.org (ILCN/WCLC)
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA | SpringerLink
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden | NEJM
Immunotherapy Advances - ASCO 2020: Key Lung Cancer Studies - Lung Cancer - 2020 ASCO Annual Meeting - Oncology - Clinical Care Options
JTO & JTO CRR on Twitter: "In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival versus chemotherapy in patients w/tumor programmed death-ligand 1 greater than or equal to 1% (primary end point)
TMB as a Biomarker for NSCLC Therapy: Could New Developments Herald a Resurgence?
New CheckMate-227 5-Year Data Show Substantial Survival Benefit of Combination Immunotherapy for Metastatic Non–Small Cell Lung Cancer
OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. | Semantic
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect
Pharmaceuticals | Free Full-Text | First line Immunotherapy for Non-Small Cell Lung Cancer
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer | NEJM
2021 Midyear Review: Non–Small-Cell Lung Cancer | Personalized Medicine in Oncology
Immunotherapy in Advanced Lung Cancer
Frontiers | Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
Bristol might play a role in front-line lung cancer after all | Evaluate
ESMO 2022: Treatment switching adjustment of overall survival in the CheckMate 227 clinical trial of nivolumab plus ipilimumab versus chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer
🇨🇦🏥🥷 Twitterren: "But not to worry: CHECKMATE-227 is hear to save the day! WOW look at those sweet PFS curves... and independent of PD-L1! Who needed that test anyway when I can
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update - ESMO Open
